Joy Gibson, MD, PhD

Dr. Gibson’s laboratory seeks to optimize treatment regimens for challenging infections. Our primary focus is management of drug-resistant bacterial infections in cystic fibrosis, particularly non-tuberculous mycobacteria. We utilize a hollow fiber infection model to optimize current therapeutics and test novel treatment approaches in vitro.

• Time-dependent pharmacodynamics of amikacin on Mycobacterium abscessus growth and resistance emergence Microbiol Spectr. 2024; 12(2). . View in PubMed
• Growth medium and nitric oxide alter Mycobacterium abscessus morphotype and virulence Microbiol Res. 2021 Dec; 253:126887. . View in PubMed

• Gilliland, Frank
• Eckel, Sandrah
• Klausner, Jeffrey
• Neely, Michael
• Cadenas, Enrique